Detalhe da pesquisa
1.
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Nature
; 600(7890): 727-730, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34912120
2.
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Lancet
; 402(10418): 2197-2208, 2023 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871604
3.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Invest New Drugs
; 42(1): 145-159, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324085
4.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol
; 186: 182-190, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38718741
5.
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study.
Gastric Cancer
; 27(1): 118-130, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37906316
6.
Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
Bioorg Chem
; 143: 107061, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38154386
7.
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
Cancer
; 129(8): 1195-1204, 2023 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748723
8.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
N Engl J Med
; 382(25): 2419-2430, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469182
9.
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Jpn J Clin Oncol
; 53(3): 221-229, 2023 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533429
10.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(2): 234-247, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030335
11.
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
Cancer
; 128(5): 995-1003, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34878659
12.
Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.
Clin Chem
; 68(12): 1519-1528, 2022 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36306340
13.
Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Hepatology
; 74(4): 1914-1931, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33884649
14.
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
Gastric Cancer
; 25(1): 207-217, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480657
15.
PD-L1 expression and overall survival in Asian and western patients with gastric cancer.
Future Oncol
; 18(21): 2623-2634, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35616013
16.
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.
Gut
; 70(5): 829-837, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33028667
17.
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 22(12): 1740-1751, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793719
18.
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
J Hepatol
; 74(2): 350-359, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32810553
19.
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Breast Cancer Res Treat
; 189(3): 665-676, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34553296
20.
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Invest New Drugs
; 39(5): 1366-1374, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33723724